Conference Proceedings
Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study
Julia Scarisbrick, Steven M Horwitz, H Miles Prince, Sean Whittaker, Madeleine Duvic, Youn H Kim, Pietro Quaglino, Pier Luigi Zinzani, Oliver Bechter, Herbert Eradat, Lauren Pinter-Brown, Oleg Akilov, Larisa Geskin, Jose Sanches, Pablo Ortiz-Romero, Julie Lisano, Lisa Brown, Veronica Bunn, Meredith Little, Reinhard Dummer
EUROPEAN JOURNAL OF CANCER | ELSEVIER SCI LTD | Published : 2019